By Fineline Cube 
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval in China to conduct a Phase Ib/II study of its small molecule KRAS G12C inhibitor SY-5933. The study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of SY-5933 when combined with conteltinib (CT-707), an ALK/FAK/PYK2/IGF1R kinase inhibitor, in patients with advanced solid tumors harboring KRAS G12C mutations.
Previous Phase I Study Results
In the Phase I dosage escalation and expansion study concluded in 2024, SY-5933 demonstrated favorable pharmacokinetic profiles in patients and showed significant anti-tumor activity across various KRAS G12C mutation tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. The drug was also found to be well tolerated by patients.-Fineline Info & Tech